Genetic Predictors to Acupuncture Response for Arthralgia Induced by Aromatase Inhibitors in Patients With Breast Cancer

Inclusion Criteria:

1. History of stage I-III breast cancer and free of disease by clinical examination;Currently receiving aromatase inhibitors (Anastrozole, Letrozole, or Exemestane) treatment;
2. AI-assisted treatment has lasted for more than one month, and there are obvious symptoms of arthralgia ;
3. Voluntarily participate in the clinical trial and sign the informed consent form after informed consent (patients voluntarily accept the treatment and give informed consent);
4. Eastern Cooperative Oncology Group (ECOG) score of physical condition (0-1);
5. Patients with previous local recurrence were eligible, but not patients with distant metastasis;
6. The basic indexes were consistent, and the blood routine and ECG were normal.

Exclusion Criteria:

1. Patients with needle phobia;
2. Low platelet count (\<50000); comorbidity with a bleeding disorder; comorbidity with thyroid dysfunction; pregnancy; haemoglobin levels \<10 g/dl and haematocrit \<30; anaemia on active pharmacological treatment orreceiving blood transfusion or steroids;
3. Lymphoedematous of limbs;
4. Patients have a history of acupuncture treatment for 6 months;
5. Patients were reluctant to participate in the study;
6. A prior history of inflammation, metabolic disease, or neurotic joints, except for previous treatment with bisphosphonates, steroids, or opioid analgesics.